UNSPSC 51151665: Zamifenacin

This classification denotes an antimuscarinic agent with the molecular formula C27H29NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y88Q418Y7M, chemically known as piperidine, 1-(2-(1,3-benzodioxol-5-yl)ethyl)-3-(diphenylmethoxy)-, (+-)- but generally known as zamifenacin, which bears US NIH Compound Identifier 124431. European Medicines Agency schedules Zamifenacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00136MIG.

UNSPSC 51151665 Zamifenacin is a Commodity code that captures pharmaceutical products purchased by state and local health agencies. Recent solicitations show state and local procurement activity centered on naloxone and drug deactivation systems rather than zamifenacin specifically — a mismatch suggesting the code's recent activity does not align closely with its nominal pharmaceutical scope. The issuing bodies soliciting under or near this code include county health departments and state health and human services commissions. Seminole County, Florida posted an IFB on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with a response deadline of July 26, 2023, and quarterly delivery requirements to the county's community health building. The Texas Health and Human Services Commission issued an RFI on April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer prescription program without specifying zamifenacin or related products.

The code shows sparse recent activity explicitly tied to zamifenacin or its direct therapeutic class. Geographic activity appears concentrated in Florida and Texas based on the two named opportunities. The Seminole County procurement requires compliance with drug-free workplace certification, E-Verify, and FEMA-related federal regulations including the Clean Air Act and Federal Water Pollution Control Act, with an initial two-year contract term and optional one-year renewal. The Texas RFI functions as market intelligence gathering rather than a formal competitive solicitation, designed to inform future state procurement strategy for direct pharmaceutical contracting outside existing pharmacy benefit manager and group purchasing organization channels. Neither opportunity explicitly identifies set-aside designations or budget allocations. Vendors pursuing this code should verify current sourcing patterns and issuing-body engagement, as recent state and local opportunities tagged to this code do not consistently reflect zamifenacin procurement.